Solo Metadatos

Neuropsychiatric SLE: From animal model to human

Título de la revista
Pikman R.
Kivity S.
Levy Y.
Arango M.-T.
Chapman J.
Yonath H.
Shoenfeld Y.
Gofrit S.G.



ISSN de la revista
Título del volumen
SAGE Publications Ltd

Buscar en:

Métricas alternativas

Animal models are a key element in disease research and treatment. In the field of neuropsychiatric lupus research, inbred, transgenic and disease-induced mice provide an opportunity to study the pathogenic routes of this multifactorial illness. In addition to achieving a better understanding of the immune mechanisms underlying the disease onset, supplementary metabolic and endocrine influences have been discovered and investigated. The ever-expanding knowledge about the pathologic events that occur at disease inception enables us to explore new drugs and therapeutic approaches further and to test them using the same animal models. Discovery of the molecular targets that constitute the pathogenic basis of the disease along with scientific advancements allow us to target these molecules with monoclonal antibodies and other specific approaches directly. This novel therapy, termed 'targeted biological medication' is a promising endeavor towards producing drugs that are more effective and less toxic. Further work to discover additional molecular targets in lupus' pathogenic mechanism and to produce drugs that neutralize their activity is needed to provide patients with safe and efficient methods of controlling and treating the disease. © The Author(s), 2016.
Palabras clave
Autoantibody , animal , Brain antigen , Cardiolipin antibody , Complement , Complement inhibitor , Crry ig , Cyclophosphamide , Cytokine , Fisle 412 peptide , Hcdr1 peptide , Immunoglobulin , Intercellular adhesion molecule 1 antibody , N methyl dextro aspartic acid receptor antibody , N methyl dextro aspartic acid receptor nr2 antibody , P 140 peptide , Peptide fragment , Ribosomal p antibody , Unclassified drug , Vitamin d , Autoantibody , Cytokine , Apoptosis , Article , Biological therapy , Blood brain barrier , Brain metabolism , Cell phagocytosis , Dietary supplement , Genetic susceptibility , Human , Immunoregulation , Mental disease , Murphy roths large lymphoproliferative mouse , Neuroendocrine system , Neuropsychiatric systemic lupus erythematosus , Nonhuman , Nzbxnzw f1 mouse , Pathogenesis , Priority journal , Systemic lupus erythematosus , Vaccination , Animal , Brain vasculitis , Disease model , Genetic predisposition , Genetics , Metabolism , Mouse , Pathology , Transgenic animal , Animals , Animals , Autoantibodies , Cytokines , Disease models , Genetic predisposition to disease , Humans , Lupus vasculitis , Mice , Animal models , Lupus , Neuropsychiatric , Targeted biological medication
Buscar en: